For instance, the development of a peptidomimetic agent acting as an ATIC homodimerization inhibitor (for tumor growth targeting) was possible by screening peptides with a novel directed evolution strategy—SICLOPPS—by Tavassoli et al. [41], which took a decade to complete [42,43,44]. Here, ATIC is linked to neoplasm.